Mental health technology

Digital reach.
Human relevance.

JAAQ combines mental health content and digital engagement with a clinically governed approach, serving organisations that want to connect people with information and support.

£3mReported contracted revenue
2026
1.5mLives described as reached
through Bupa
£12.5mCumulative funding reported
August 2026

Management-reported figures, August 2026. A separate public March 2026 announcement reports $17m in funding; these amounts are not added together. Reach is not a measure of active use or clinical outcomes. Contracted revenue is distinct from revenue recognised and cash received.

Meeting people
where they are.

JAAQ’s business model focuses on organisational relationships and digital delivery. Its reported customers include Bupa, NatWest, Nationwide and Workday.

For investors, the opportunity is to understand how those relationships translate into sustained engagement, renewals and expansion. JAAQ reported 100% net revenue retention in August 2026, a figure to assess alongside its measurement period and customer base.

The commercial opportunity

  • Deepening existing employer and insurer relationships.
  • Extending digital access across markets and customer populations.
  • Combining engaging content with appropriate clinical governance.

Leadership and backing

Experience across
technology and health.

Led by CEO Alex Packham, JAAQ has board members and backers with experience across business, healthcare and venture investing, including Simon Morris, Paul Thandi, Guinness Ventures, Meridian Health Ventures and Fuel Ventures.

Steve Bolton serves as an Investor Director. Bolt reports supporting the finance function during the seed stages and helping appoint the CEO.

Progress to follow.
Evidence to review.

Expansion and customer adoption

JAAQ’s expansion priorities include international rollout through Bupa and additional customer relationships. Delivery and adoption remain key measures of progress.

Clinical development

As at August 2026, an NHS Trust clinical validation programme and Class I medical device certification work were in progress.

Investor diligence

Review renewal economics, engagement, customer concentration, clinical governance and the capital needed for expansion.

Read the public funding announcement ↗

Continue the conversation

Go deeper.
Ask the questions.

Discuss the businesses, the investment case and the information you need with Steve Bolton.

Speak with Steve ↗